Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics (Nasdaq: OTLK) closed a public offering on March 25, 2026, selling 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares at a combined public offering price of $0.25 per share and warrant.
The offering generated aggregate gross proceeds of $5.0 million before fees; the warrants have a $0.25 exercise price, are exercisable immediately and expire five years from issuance. The company intends to use net proceeds primarily for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) priced a public offering of 20,000,000 shares and accompanying warrants to buy 20,000,000 shares at a combined price of $0.25 per share/warrant, yielding aggregate gross proceeds of $5.0 million before fees.
Each warrant is exercisable immediately at $0.25 and expires five years from issuance; the offering is expected to close on or about March 25, 2026.
Outlook Therapeutics (Nasdaq: OTLK) announced on March 23, 2026 that it has commenced a best-efforts public offering of common stock (or pre-funded warrants) and accompanying warrants exercisable for common stock. The offering is subject to market and other conditions and may not be completed.
H.C. Wainwright is the exclusive placement agent. Net proceeds are intended primarily for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (File No. 333-278340); a prospectus supplement will be filed with the SEC.
Outlook Therapeutics (Nasdaq: OTLK) announced an amendment and a new financing on March 16, 2026. The company extended the Avondale convertible note maturity to Dec 31, 2026 and issued an $18.4 million non-convertible unsecured note to Atlas Sciences.
Outlook expects $17.0 million net proceeds after original issue discount, will use proceeds to pay down the Existing Note leaving ~$10.8 million of principal and interest, and the New Note matures on June 16, 2027 with interest = Prime + 3% (minimum 9.5% per annum).
Outlook Therapeutics (Nasdaq: OTLK) provided a regulatory update after a Type A meeting with the U.S. FDA regarding the Dec 30, 2025 Complete Response Letter for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg). The meeting focused on the FDA’s outstanding substantial-evidence issue and potential paths to approval.
NORSE TWO met its primary and key secondary endpoints with clinically meaningful, statistically significant visual-acuity improvements; NORSE EIGHT and other data were submitted as confirmatory evidence. The FDA identified no safety concerns. The company is evaluating regulatory options and continuing discussions to clarify confirmatory evidence and next steps toward potential U.S. approval.
Outlook Therapeutics (Nasdaq: OTLK) signed an exclusive commercial distribution agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland. Mediconsult will seek Marketing Authorization, import, distribute and commercialize LYTENAVA™, which Outlook will manufacture and supply.
LYTENAVA™ is expected to launch in Switzerland in 2027, subject to regulatory approval.
Outlook Therapeutics (Nasdaq: OTLK) reported Q1 FY2026 results and a regulatory update on Feb 17, 2026. The company recorded a $23.1M net loss ($0.38/share) and an adjusted net loss of $13.5M ($0.22/share). Unit sales of LYTENAVA more than doubled quarter-over-quarter and Austria launched in January 2026. A Type A meeting request was submitted to the FDA following a Dec 30, 2025 CRL for ONS-5010.
Outlook Therapeutics (Nasdaq: OTLK) submitted a Type A meeting request to the FDA on Feb 11, 2026 after receiving a Complete Response Letter (Dec 30, 2025) for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) in wet AMD. The CRL cited a single deficiency alleging lack of substantial evidence of effectiveness and requested additional confirmatory evidence.
The company cites positive Phase 3 NORSE TWO results at 12 months, complementary data from NORSE EIGHT, mechanistic/pharmacodynamic evidence, favorable safety findings, and existing EU and UK marketing authorizations.
Outlook Therapeutics (Nasdaq: OTLK) on January 6, 2026 appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.
Ms. Cantrell brings more than 20 years of global biotechnology experience in corporate strategy, business development and portfolio leadership, and will lead strategic partnerships, licensing and corporate development initiatives as the company advances a differentiated ophthalmic formulation of bevacizumab.
Her background includes senior roles at Medivation (part of a team supporting a $14 billion acquisition by Pfizer), BeiGene, Sobi, Axovant Sciences, and Genentech/Roche; she holds an MBA from Emory and a BS in Biology from University of Michigan.
Outlook Therapeutics (Nasdaq: OTLK) said the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the resubmitted biologics license application for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD), indicating the application cannot be approved in its present form.
The FDA noted one adequate and well-controlled study demonstrated efficacy but again requested confirmatory evidence of efficacy and did not specify what evidence would be acceptable. The resubmission was based on the NORSE clinical program (including NORSE TWO and NORSE EIGHT).
Outlook said it is exploring U.S. approval pathways and continuing commercial expansion in Europe, where LYTENAVA received European Commission and MHRA marketing authorizations and became commercially available in Germany and the UK in June 2025.